Mechanisms of action of anti-tumor necrosis factor α agents in Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 7, 2013, Pages 1546-1555

  Peake, Simon T C ^a,b   Bernardo, David ^a   Mann, Elizabeth R ^a   Al Hassi, Hafid O ^a   Knight, Stella C ^a   Hart, Ailsa L ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Anti TNF ; Apoptosis; Infliximab; Mechanisms of action; Paradoxical inflammation

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CROHN DISEASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; IMMUNOTHERAPY; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CROHN DISEASE; HUMANS; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879086432     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318281333b     Document Type: Review

References (89)

1. Crohn BB, Ginzburg L, Oppenheimer GD. Landmark article Oct. 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA. 1984;251:73-79.
2. Hanauer SB. The expanding role of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7:63-64.
3. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72:3666-3670.
4. Chowers Y, Allez M. Efficacy of anti-TNF in Crohn's disease: how does it work? Curr Drug Targets. 2010;11:138-142.
5. Kollias G. TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum. 2005;34:3-6.
6. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339:89-91.
7. Van Deventer SJ. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease-the mechanisms of action of infliximab. Aliment Pharmacol Ther. 1999;13(Suppl 4):3-8; discussion 38.
8. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411-452.
9. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-1725.
10. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729-733.
11. Vandenabeele P, Declercq W, Beyaert R, et al. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5:392-399.
12. Wallach D, Varfolomeev EE, Malinin NL, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999;17:331-367.
13. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994;76:959-962.
14. Corazza N, Brunner T, Buri C, et al. Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology. 2004;127:816-825.
15. Eissner G, Kirchner S, Lindner H, et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol. 2000;164:6193-6198.
16. Harashima S, Horiuchi T, Hatta N, et al. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol. 2001;166:130-136.
17. Ringheanu M, Daum F, Markowitz J, et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis. 2004;10:801-810.
18. Di Sabatino A, Liberato L, Marchetti M, et al. Optimal use and costeffectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6(Suppl 1):17-27.
19. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
20. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
21. Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
22. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
23. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut. 2009;58:492-500.
24. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
25. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008:CD006893.
26. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
27. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
28. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
29. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
30. Breese E, MacDonald TT. TNF alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol. 1995;371 B: 821-824.
31. Ten Hove T, Van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211.
32. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-279.
33. Gramlick A, Fossati G, Nesbitt AM. Neutralization of soluble and membrane tumor necrosis factor-alpha (TNF-alpha) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-alpha receptor-specific bioassays. Gastroenterology. 2006;130:A697.
34. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418-426.
35. Mitoma H, Horiuchi T, Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology. 2004;126:934-935; author reply 935-936.
36. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent antiinflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology. 2005;128:376-392.
37. Turner JR, Rill BK, Carlson SL, et al. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol. 1997;273:C1378-C1385.
38. Gassler N, Rohr C, Schneider A, et al. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol. 2001;281:G216-G228.
39. Poritz LS, Lynch CJ, Tilberg AF, et al. Decreased expression of occludin in the intestine of patients with inflammatory bowel disease. FASEB J. 1997;11:1800.
40. Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. 2003;171:6164-6172.
41. Wang F, Graham WV, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol. 2005;166:409-419.
42. Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut. 2004;53:1295-1302.
43. Fries W, Muja C, Crisafulli C, et al. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. Am J Physiol Gastrointest Liver Physiol. 2008;294:G938-G947.
44. Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol. 2002;97:2000-2004.
45. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol. 1999;163:1081-1090.
46. Arnold R, Brenner D, Becker M, et al. How T lymphocytes switch between life and death. Eur J Immunol. 2006;36:1654-1658.
47. Brady HJ, Gil-Gomez G, Kirberg J, et al. Bax alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J. 1996;15:6991-7001.
48. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614-620.
49. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-1326.
50. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology. 1999;116:557-565.
51. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157.
52. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut. 2004;53:70-77.
53. Atreya R, Zimmer M, Bartsch B, et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14 macrophages. Gastroenterology. 2011;141:2026-2038.
54. Van Den Brande JM, Koehler TC, Zelinkova Z, et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut. 2007;56:509-517.
55. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005;21:251-258.
56. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13:1323-1332.
57. Szekanecz Z, Besenyei T, Szentpetery A, et al. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol. 2010;22:299-306.
58. Danese S, Sans M, De La Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130:2060-2073.
59. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009;136:585-595.e5.
60. Rutella S, Fiorino G, Vetrano S, et al. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. Am J Gastroenterol. 2011;106:762-770.
61. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289-298.
62. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009;58:1152-1167.
63. Nesbitt AM, Fossati G, Brown DT. Comparison of certolizumab pegol, etanercept, adalimumab and infliximab: Effect on lipopolysaccharideinduced cytokine production by human peripheral blood monocytes. Am J Gastroenterol. 2006;101:S436-S437.
64. Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine. 2001;15:212-222.
65. Mizutani T, Akasaka R, Tomita K, et al. Serial changes of cytokines in Crohn's disease treated with infliximab. Hepatogastroenterology. 2011;58:1523-1526.
66. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-869.
67. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
68. Tilg H, Moschen A, Kaser A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Expert Opin Biol Ther. 2007;7:1051-1059.
69. Danese S, Sans M, Scaldaferri F, et al. TNF-alpha blockade downregulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006;176:2617-2624.
70. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005;129:50-65.
71. Danese S, Sans M, Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut. 2004;53:1035-1043.
72. Bernardo D, Al-Hassi HO, Mann ER, et al. T-cell proliferation and forkhead box P3 expression in human T cells are dependent on T-cell density: physics of a confined space? Hum Immunol. 2012;73:223-231.
73. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004;200:277-285.
74. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007;204:33-39.
75. Vos AC, Wildenberg ME, Arijs I, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis. 2012;18:401-408.
76. Toruner M, Loftus Jr EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
77. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
78. Chowers Y, Sturm A, Sans M, et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis. 2010;4:367-376.
79. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-1055.
80. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501-508.
81. Esmailzadeh A, Yousefi P, Farhi D, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology. 2009;219:263-267.
82. Toussirot E, Houvenagel E, Goeb V, et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine. 2012;79:457-463.
83. Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFNalpha in autoimmune diseases. Proc Natl Acad Sci U S A. 2005;102:3372-3377.
84. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J ExpMed. 2005;202:135-143.
85. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: metaanalysis of randomized controlled trials. Br J Dermatol. 2008;159:513-526.
86. De Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223-231.
87. Notley CA, Inglis JJ, Alzabin S, et al. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med. 2008;205:2491-2497.
88. Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol. 2009;161:1081-1088.
89. Peake ST, Bernardo D, Mann ER, et al. Anti-TNF alpha induces a dysregulated tissue-homing profile on human immune cells in vitro. J Chrons Colitis 2012;6:S15.